Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C

Table 3 Multivariate analysis of factors associated with outcome of chronic hepatitis C treatment with pegylated interferon alpha and ribavirin

Variable	OR (95%CI)	P value
Response (SVR)1
rs4803217 (C/A)	4.979 (1.344-18.444)	0.016a
rs12979860 (C/T)	1.499 (0.446-5.042)	0.510
rs8099917 (T/G)	0.594 (0.247-1.429)	0.242
rs12980275 (A/G)	1.658 (0.598-4.594)	0.328
Stage of fibrosis	3.278 (1.108-9.698)	0.031a
Relapse2
rs4803217 (C/A)	0.134 (0.023-0.789)	0.024a
rs12979860 (C/T)	2.381 (0.444-12.773)	0.303
rs12980275 (A/G)	1.046 (0.369-2.961)	0.932

¹Model summary: χ² (5) = 56.028; P < 0.0001, constant: < 0.0001. rs4803217, rs12979860, rs8099917, rs12980275 (dose allele model) an stage of fibrosis were included in the analysis;

²Model summary: χ² (3) = 12.337, P < 0.00632, constant: P = 0.019. rs4803217, rs12979860, and rs12980275 (dose allele model) were included in the analysis.

^aP < 0.05 (independent factors). SVR: Sustained virological response.